SNY Sanofi American Depositary Shares (Each representing one-half of one ordinary share) Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:00
Aug 04
Aug 04
Pfizer plans to start a Phase 3 trial for a bispecific antibody directly vs. Dupixent, powered for superiority, in a head-to-head setting. — A potential weekly alternative to Dupixent could challenge Sanofi's franchise in atopic dermatitis and asthma.
MED
12:00
Jul 31
Jul 31
Moderna's flu vaccine (mRNA-1010) has the capability to update its strain selection in under two months, a potential flexibility advantage over incumbent flu vaccines in response to late-season strain mismatches. — A late strain update capability could allow Moderna to offer a better-matched vaccine in a given season, potentially shifting market share from incumbent flu vaccine makers.
MED
12:30
Jul 30
Jul 30
The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits. — A new, higher-margin, recurring profit share kicks in following the repayment.
HIGH
08:25
Jul 30
Jul 30
Sanofi reported better-than-expected profit growth and raised its guidance due to strong demand.
Sanofi reported better-than-expected profit growth and raised its guidance due to strong demand for its top-selling drug Dupixent.
16:52
Jul 27
Jul 27
The author discloses a short position in SLS based on a high probability of trial failure.
The author discloses a short position in SLS based on a high probability of trial failure and expresses bearish views on CAPR and INBX while maintaining a portfolio of long biotech positions and watching several others for potential additions.
03:59
Jul 27
Jul 27
The author speculates on a chain of events involving SNY halting a drug trial benefiting NKTR.
The author speculates on a chain of events involving SNY halting a drug trial benefiting NKTR and potentially leading to an ABVX acquisition, but presents it as a humorous hypothetical rather than a concrete position.
22:34
Jul 26
Jul 26
Peak earnings season begins with 177 S&P 500 companies reporting Q2 results this week.
Peak earnings season begins with 177 S&P 500 companies reporting Q2 results this week, including mega caps like Apple, Amazon, and Microsoft.
01:28
Jul 26
Jul 26
The author provides a speculative likelihood matrix of potential acquirers for ABVX.
The author provides a speculative likelihood matrix of potential acquirers for ABVX, framing the list as research context rather than an explicit trade recommendation.
LOW
18:34
Jul 25
Jul 25
The author speculates that a clinical trial halt for Sanofi could benefit Nektar Therapeutics.
The author speculates that a clinical trial halt for Sanofi could benefit Nektar Therapeutics and potentially trigger an acquisition of Abivax.
LOW
17:29
Jul 25
Jul 25
The author discusses potential acquisition interest in ABVX by major pharmaceutical companies.
The author discusses potential acquisition interest in ABVX by major pharmaceutical companies like SNY and JNJ to maintain market relevance.
LOW
15:20
Jul 24
Jul 24
Author notes Sanofi already invested in Bionyra with HLE IL23 and TL1a.
Author notes Sanofi already invested in Bionyra with HLE IL23 and TL1a, suggesting no reason to pursue SYRE or ORKA at extreme expense.
12:51
Jul 24
Jul 24
Author argues SNY already has relevant assets and sees no reason to pursue SYRE or ORKA at high.
Author argues SNY already has relevant assets and sees no reason to pursue SYRE or ORKA at high cost, but does not state a personal position.
LOW
12:36
Jul 24
Jul 24
Author questions the rationale behind SNY's potential acquisition of SYRE given overlapping.
Author questions the rationale behind SNY's potential acquisition of SYRE given overlapping assets, expressing skepticism without taking a directional position.
LOW
11:16
Jul 24
Jul 24
Avoid SNY: author says Sanofi has lost amlitelimab, riliprubart.
Avoid SNY: author says Sanofi has lost amlitelimab, riliprubart, and faces Dupixent LOE pressure, implying pipeline/revenue holes; bearish view without explicit short.
LOW
11:07
Jul 24
Jul 24
Avoid SNY: author says Sanofi discontinued amlitelimab over safety concerns after previously.
Avoid SNY: author says Sanofi discontinued amlitelimab over safety concerns after previously promoting it as a multi-billion-dollar peak sales drug; negative company/pipeline view without explicit short.
MED
05:41
Jul 24
Jul 24
SNY announced it will not submit amlitelimab for atopic dermatitis globally.
SNY announced it will not submit amlitelimab for atopic dermatitis globally; a regulatory setback event for the drug.
LOW
16:58
Jul 16
Jul 16
AlphaSense reports that AI in healthcare is delivering measurable ROI across pharma, payers.
AlphaSense reports that AI in healthcare is delivering measurable ROI across pharma, payers, and providers with real-world implementations at UnitedHealth, Eli Lilly, and Sanofi.
09:56
Jun 26
Jun 26
Sanofi is under investigation by European Commission watchdogs over suspicions it illegally.
Sanofi is under investigation by European Commission watchdogs over suspicions it illegally disparaged a rival flu vaccine.
09:50
Jun 26
Jun 26
The European Union has launched a formal antitrust investigation into Sanofi over alleged.
The European Union has launched a formal antitrust investigation into Sanofi over alleged misleading claims against CSL Seqirus' flu vaccine.
15:13
Jun 22
Jun 22
The author questions the high valuations of HLE mAb companies like SYRE and ORKA.
The author questions the high valuations of HLE mAb companies like SYRE and ORKA, noting SNY's investment, but does not state a personal position or explicit directional call.
LOW
11:53
Jun 22
Jun 22
The author declares OX40 target dead and questions SNY's Amlitelimab continuation.
The author declares OX40 target dead and questions SNY's Amlitelimab continuation, but provides no personal position or forward trade call.
LOW
03:40
Jun 17
Jun 17
The author presents a factual analysis of M&A activity in the biotech sector since Covid.
The author presents a factual analysis of M&A activity in the biotech sector since Covid, noting that many large pharma companies have not yet engaged in significant deals, but does not express a personal position or forward-looking trade call.
LOW
13:50
Jun 10
Jun 10
Author dismisses M&A speculation for SNY, calling company-specific deal predictions a fool's.
Author dismisses M&A speculation for SNY, calling company-specific deal predictions a fool's errand without taking a directional position.
LOW
12:06
Jun 10
Jun 10
Speaker highlights pipeline disappointments for SNY’s I&I drugs.
Speaker highlights pipeline disappointments for SNY’s I&I drugs, implying a need for M&A to fill gaps; no directional trade.
MED
06:23
Jun 10
Jun 10
Sanofi halts a late-stage trial of an experimental drug, increasing pressure on its new CEO.
03:24
Jun 07
Jun 07
Sanofi's AI deal with Owkin highlights the company's research and development shift.
Sanofi's AI deal with Owkin highlights the company's research and development shift and valuation focus according to a Yahoo report.
12:56
May 08
May 08
Adam May argues Nektar Therapeutics' bold Phase 3 strategy for Rezpeg in atopic dermatitis.
Adam May argues Nektar Therapeutics' bold Phase 3 strategy for Rezpeg in atopic dermatitis, including a biologic-refractory trial no pharma giant has run, could drive over $5B in peak sales and make NKTR a glaring M&A candidate at current prices.
HIGH
19:05
Apr 29
Apr 29
Adam May replies to Benjo McKazuie by simply listing the tickers $AZN, $LLY.
Adam May replies to Benjo McKazuie by simply listing the tickers $AZN, $LLY, and $SNY without any directional opinion or market context.
LOW
12:30
Apr 29
Apr 29
Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue. — This is a significant, durable revenue tailwind for Regeneron from Q3 onwards.
HIGH
About SNY Analyst Coverage
Buzzberg tracks SNY (Sanofi American Depositary Shares (Each representing one-half of one ordinary share)) across 7 sources. 0 bullish vs 1 bearish calls from 14 analysts. Sentiment: mixed to bearish. 42 total trade ideas tracked. Past 7 days: 4 watch. Latest voices: Chris Boshoff, Stephen Hoge, Dr. Leonard Schleifer.